Common pitfalls in preclinical cancer target validation

Nature Reviews. Cancer
William G Kaelin

Abstract

An alarming number of papers from laboratories nominating new cancer drug targets contain findings that cannot be reproduced by others or are simply not robust enough to justify drug discovery efforts. This problem probably has many causes, including an underappreciation of the danger of being misled by off-target effects when using pharmacological or genetic perturbants in complex biological assays. This danger is particularly acute when, as is often the case in cancer pharmacology, the biological phenotype being measured is a 'down' readout (such as decreased proliferation, decreased viability or decreased tumour growth) that could simply reflect a nonspecific loss of cellular fitness. These problems are compounded by multiple hypothesis testing, such as when candidate targets emerge from high-throughput screens that interrogate multiple targets in parallel, and by a publication and promotion system that preferentially rewards positive findings. In this Perspective, I outline some of the common pitfalls in preclinical cancer target identification and some potential approaches to mitigate them.

References

Dec 10, 1999·The Journal of Clinical Investigation·W G Kaelin
Sep 6, 2003·Cancer Cell·Barbara BlouwGabriele Bergers
Aug 5, 2004·Journal of the National Cancer Institute·Chiara BrignoleMirco Ponzoni
Feb 8, 2005·Proceedings of the National Academy of Sciences of the United States of America·Ralf KittlerFrank Buchholz
Feb 12, 2005·Proceedings of the National Academy of Sciences of the United States of America·Michael R BurgessCharles L Sawyers
Aug 20, 2005·Nature Reviews. Cancer·William G Kaelin
Sep 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A L HamiltonF M Muggia
Sep 7, 2007·Cancer Metastasis Reviews·Howard R Mellor, Adrian L Harris
Nov 17, 2009·Proceedings of the National Academy of Sciences of the United States of America·Caroline M EmeryLevi A Garraway
Sep 8, 2010·The New England Journal of Medicine·Keith T FlahertyPaul B Chapman
Sep 6, 2011·Nature Reviews. Drug Discovery·Florian PrinzKhusru Asadullah
Dec 16, 2011·Nature Reviews. Cancer·Brian KeithM Celeste Simon
Feb 14, 2012·Nature Chemical Biology·Sarah A WackerTarun M Kapoor
Mar 31, 2012·Nature·C Glenn Begley, Lee M Ellis
Jun 16, 2014·Nature Chemical Biology·Corynn KasapTarun M Kapoor
Dec 11, 2014·ELife·Timothy M ErringtonBrian A Nosek
Sep 22, 2015·Nature Reviews. Drug Discovery·Stephen V FryeBarbara S Slusher
May 18, 2016·Nature Chemical Biology·Ting HanDeepak Nijhawan
Jun 5, 2016·Cancer Discovery·Andrew J AguirreWilliam C Hahn
Nov 8, 2016·Nature Chemical Biology·Josep V FormentStephen P Jackson
Jan 20, 2017·ELife·Brian A Nosek, Timothy M Errington

❮ Previous
Next ❯

Citations

Sep 26, 2017·Angewandte Chemie·Richard J D HatleyPauline T Lukey
Mar 13, 2018·ELife·Thomas D BairdJ Robert Hogg
May 9, 2018·Expert Opinion on Drug Discovery·Wilian Augusto CortopassiAntoniana Ursine Krettli
Jan 18, 2018·Medicinal Research Reviews·Yuan QuanHong-Yu Zhang
Sep 20, 2017·ELife·Hai-Tsang HuangNathanael S Gray
Sep 19, 2018·PLoS Biology·Thomas StoegerLuís A Nunes Amaral
Oct 30, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David F McDermott, Michael Carducci
Feb 5, 2019·GigaScience·Mark N WassMartin Michaelis
Aug 26, 2018·EMBO Molecular Medicine·Alexander GreenhoughAnn C Williams
Aug 2, 2019·Blood·Haijiao ZhangJeffrey W Tyner
Dec 11, 2019·Nature Chemical Biology·Michael A Erb
Jul 14, 2017·Science Translational Medicine·Abhishek A ChakrabortyWilliam G Kaelin
Feb 28, 2019·The Oncologist·Laura FranshawDavid S Ziegler
Jul 27, 2017·SLAS Discovery·John S LazoElizabeth R Sharlow
Feb 18, 2020·Current Hematologic Malignancy Reports·HeeJin CheonThomas P Loughran
Jan 10, 2020·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Barbara C SorkinGuido F Pauli
Jun 21, 2020·Nature Reviews. Genetics·Ann Lin, Jason M Sheltzer
Oct 19, 2017·Science China. Life Sciences·Yanqing HuangCullen M Taniguchi
May 3, 2018·Oncogene·Shelli M MorrisRichard A Klinghoffer
Dec 23, 2017·Frontiers in Pharmacology·Jayne-Louise E PritchardDylan M Glubb
Dec 4, 2019·Annals of the New York Academy of Sciences·Jennifer CableWilliam Kaelin
Sep 15, 2019·Disease Models & Mechanisms·Faye L RobertsonSteven M Pollard
Nov 30, 2019·Future Medicinal Chemistry·Albert A AntolinBissan Al-Lazikani
Mar 10, 2018·Frontiers in Immunology·María Elena IezziGabriela Alicia Canziani
Aug 17, 2018·Open Biology·J R de RuiterJ Jonkers
Jun 5, 2019·Genes & Development·Ryan C GimpleJeremy N Rich
Oct 10, 2020·Nature Communications·M Martinez-LageS Rodriguez-Perales
Jul 28, 2020·Advanced Drug Delivery Reviews·Fangli MoWeihong Tan
Feb 7, 2021·Science Advances·Vidyasagar KoduriWilliam G Kaelin
Feb 17, 2021·Cell Chemical Biology·Jayme L DahlinBridget K Wagner
Nov 18, 2020·Nature Reviews. Drug Discovery·Christoph H EmmerichMichael J Parnham
Mar 6, 2021·Molecular Therapy. Nucleic Acids·Marion T J van den BoschMichel Janicot
Mar 19, 2019·Current Opinion in Chemical Biology·Rhushikesh A KulkarniJordan L Meier

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.